Back to Search

MAURICIO PINEDA-ROMAN, MD

MD

Hematology (Internal Medicine) Physician

NPI: 1518057090IndividualAccepts Medicare

Specialties, Licenses & Credentials

Internal Medicine Physician

Internal Medicine

Code: 207R00000X

2017-02171(NC)
Hematology (Internal Medicine) PhysicianPrimary

Internal Medicine — Hematology

Code: 207RH0000X

2017-02171(NC)
Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

2017-02171(NC)
Medical Oncology Physician

Internal Medicine — Medical Oncology

Code: 207RX0202X

2017-02171(NC)

CMS Specialties

PrimaryHEMATOLOGY/ONCOLOGY

Additional

INTERNAL MEDICINE

Education

OTHER

Class of 1990

Research & Publications (20)

High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
PMID 18300230·Cancer·2008
8-other
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
PMID 18432260·Leukemia·2008
3-trial
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
PMID 18302711·Br J Haematol·2008
2-rct
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
PMID 17156398·Br J Haematol·2007
2-rct
High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.
PMID 17075230·Contrib Nephrol·2007
6-review
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
PMID 18669874·Blood·2008
3-trial
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
PMID 18492953·Blood·2008
3-trial
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
PMID 18470907·Cancer·2008
8-other
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
PMID 18433012·Cancer·2008
3-trial
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
PMID 17895401·Blood·2008
8-other
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
PMID 18371114·Br J Haematol·2008
3-trial
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
PMID 17593024·Br J Haematol·2007
3-trial
The Arkansas approach to therapy of patients with multiple myeloma.
PMID 18070718·Best Pract Res Clin Haematol·2007
6-review
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
PMID 18056185·Clin Cancer Res·2007
3-trial
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
PMID 17489983·Br J Haematol·2007
8-other
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
PMID 17416735·Blood·2007
3-trial
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
PMID 17296972·J Clin Oncol·2007
3-trial
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.
PMID 17179226·Blood·2007
8-other
Hyperammonemia and encephalopathy in patients with multiple myeloma.
PMID 17133420·Am J Hematol·2007
8-other
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
PMID 17105813·Blood·2007
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 5 locations total

Address
945 N 5TH ST
ALBEMARLE, NC 28001

Locations (5)

Practice Location

945 N 5TH ST, ALBEMARLE, NC
(980) 323-7790

Practice Location

4525 CAMERON VALLEY PKWY, CHARLOTTE, NC
(704) 302-8300

Practice Location

1021 MOREHEAD MEDICAL DR, CHARLOTTE, NC
(980) 442-2000

Practice Location

100 MEDICAL PARK DR, CONCORD, NC
(704) 403-1370

Practice Location

1550 FAULK ST, MONROE, NC
(980) 442-0430

Quick Facts

NPI
1518057090
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
4
Locations
5
Years in Practice
36
Publications
20

Are you this provider?

Claim Your Profile